At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition With Pembrolizumab in Combination With PARP Inhibition With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancers
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Olaparib for Breast Cancer. Completed, enrolled 14 participants across 1 site.
Detailed Summary
This trial will evaluate the use of immunotherapy and PARP inhibition in a population with incurable advanced breast cancer associated with a germline BRCA mutation or HDR-defect. The main objective is to examine overall response rate of pembrolizumab (immunotherapy) in combination with Olaparib (PARP inhibitor) in advanced BRCA-mutated or Homology-directed repair (HDR)-defect breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartSep 2017
Primary CompletionOct 2024
Study CompletionNov 2025
TodayJul 2026
First PostedJan 19, 2017
Enrollment StartSep 10, 2017
Primary CompletionOct 8, 2024
Study CompletionNov 21, 2025
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 9.5 years ago
Interventions
Pembrolizumabdrug
Pembrolizumab IV solution administered on Day 1 of each 3-week cycle
Olaparibdrug
Olaparib administered orally twice a day